Form 4: Vor Biopharma Executive Eyal C. Attar Reports Tax-Related Stock Transaction
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma, reports the withholding of 1,180 common stock shares to cover tax obligations related to the settlement of restricted stock units on February 6, 2025.
Summary
- On February 6, 2025, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., had 1,180 shares of common stock withheld to satisfy tax obligations.
- The shares were withheld in connection with the settlement of restricted stock units.
- Following the transaction, Attar directly owns 131,406 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to tax obligations, indicating a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax-related stock withholding.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of transaction: 1,180 shares of common stock withheld for tax obligations. |
| 02/07/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.